JP2023507795A - 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン - Google Patents

第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン Download PDF

Info

Publication number
JP2023507795A
JP2023507795A JP2022538201A JP2022538201A JP2023507795A JP 2023507795 A JP2023507795 A JP 2023507795A JP 2022538201 A JP2022538201 A JP 2022538201A JP 2022538201 A JP2022538201 A JP 2022538201A JP 2023507795 A JP2023507795 A JP 2023507795A
Authority
JP
Japan
Prior art keywords
antibody
seq
drug delivery
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507795A5 (https=
Inventor
デブラ エー． フリードホルム，
ダニエル エム． ブルームフィールド，
ロイストン ジェイ． グラスプール，
ジョナサン イー． フリーマン，
Original Assignee
アントス セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アントス セラピューティクス， インコーポレイテッド filed Critical アントス セラピューティクス， インコーポレイテッド
Publication of JP2023507795A publication Critical patent/JP2023507795A/ja
Publication of JP2023507795A5 publication Critical patent/JP2023507795A5/ja
Priority to JP2025207453A priority Critical patent/JP2026048712A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022538201A 2019-12-20 2020-12-18 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン Pending JP2023507795A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025207453A JP2026048712A (ja) 2019-12-20 2025-11-28 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951887P 2019-12-20 2019-12-20
US62/951,887 2019-12-20
PCT/US2020/066151 WO2021127525A1 (en) 2019-12-20 2020-12-18 Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025207453A Division JP2026048712A (ja) 2019-12-20 2025-11-28 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン

Publications (2)

Publication Number Publication Date
JP2023507795A true JP2023507795A (ja) 2023-02-27
JP2023507795A5 JP2023507795A5 (https=) 2023-12-15

Family

ID=76478578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538201A Pending JP2023507795A (ja) 2019-12-20 2020-12-18 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
JP2025207453A Pending JP2026048712A (ja) 2019-12-20 2025-11-28 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025207453A Pending JP2026048712A (ja) 2019-12-20 2025-11-28 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン

Country Status (9)

Country Link
US (1) US20230071973A1 (https=)
EP (1) EP4076511A4 (https=)
JP (2) JP2023507795A (https=)
KR (1) KR20220119090A (https=)
CN (1) CN115003325A (https=)
BR (1) BR112022012064A2 (https=)
CA (1) CA3161118A1 (https=)
IL (1) IL293367A (https=)
WO (1) WO2021127525A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540435A (ja) * 2021-11-18 2024-10-31 アントス セラピューティクス， インコーポレイテッド 第ＸＩ／ＸＩａ因子抗体の投薬レジメン
TW202333789A (zh) * 2022-01-05 2023-09-01 大陸商上海邁晉生物醫藥科技有限公司 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途
DE102022116219A1 (de) * 2022-06-29 2024-01-04 St. Jude Medical, Cardiology Division, Inc. Kandidatenscreening für eine Zieltherapie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524595A (ja) * 2005-12-20 2009-07-02 ブリストル−マイヤーズ スクイブ カンパニー 安定なタンパク質製剤
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
JP2018526976A (ja) * 2015-06-26 2018-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100129379A1 (en) * 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
MX2018002166A (es) * 2015-08-20 2018-09-12 Abbvie Stemcentrx Llc Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
IL267519B2 (en) * 2016-12-23 2025-04-01 Novartis Ag Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease
AU2017383232B2 (en) * 2016-12-23 2024-09-12 Novartis Ag Factor XI antibodies and methods of use
US20190367636A1 (en) * 2017-01-19 2019-12-05 Bayer Pharma Aktiengesellschaft Novel stable formulation for fxia antibodies
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
JP2024540435A (ja) * 2021-11-18 2024-10-31 アントス セラピューティクス， インコーポレイテッド 第ＸＩ／ＸＩａ因子抗体の投薬レジメン

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524595A (ja) * 2005-12-20 2009-07-02 ブリストル−マイヤーズ スクイブ カンパニー 安定なタンパク質製剤
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
JP2018526976A (ja) * 2015-06-26 2018-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法

Also Published As

Publication number Publication date
KR20220119090A (ko) 2022-08-26
BR112022012064A2 (pt) 2022-08-30
EP4076511A4 (en) 2024-02-14
WO2021127525A1 (en) 2021-06-24
EP4076511A1 (en) 2022-10-26
IL293367A (en) 2022-07-01
JP2026048712A (ja) 2026-03-17
CN115003325A (zh) 2022-09-02
US20230071973A1 (en) 2023-03-09
CA3161118A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
JP7079844B2 (ja) 高濃度抗ｃ５抗体製剤
KR102857973B1 (ko) 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
TW202104270A (zh) 包含抗ｃｄ４７／ｐｄ－ｌ１雙特異性抗體的製劑及其製備方法和用途
US20240279323A1 (en) Methods for the treatment of scleroderma and related conditions
JP2023527563A (ja) ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法
JP2021535161A (ja) 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
US20240294669A1 (en) Dosing regimens of factor xi/xia antibodies
WO2018223958A1 (zh) 一种含c-Met抗体药物偶联物的药物组合物及其用途
JP2024544057A (ja) 血栓塞栓性疾患を予防及び／又は治療する方法
JP2025523506A (ja) 抗第ｘｉ因子／第ｘｉａ因子抗体との併用療法
TW202434633A (zh) 治療甲狀腺眼疾之方法
US20260022197A1 (en) Methods of reversing ticagrelor activity
CN118302196A (zh) 因子XI/XIa抗体的给药方案
EA045920B1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250702

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128